IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for IRIX
8.89
+0.08 (0.91%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.61 - 8.89
52 week 6.41 - 11.00
Open 8.76
Vol / Avg. 6,002.00/14,812.00
Mkt cap 86.71M
P/E 53.61
Div/yield     -
EPS 0.17
Shares 9.84M
Beta 1.32
Inst. own 51%
Oct 30, 2014
Q3 2014 IRIDEX Corp Earnings Call - Webcast
Oct 30, 2014
Q3 2014 IRIDEX Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.84% 5.83%
Operating margin 5.99% 6.88%
EBITD margin - 6.92%
Return on average assets 6.06% 7.13%
Return on average equity 7.66% 9.34%
Employees 101 -
CDP Score - -

Address

1212 Terra Bella Ave
MOUNTAIN VIEW, CA 94043-1824
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The main focus of the Company is on ophthalmology business. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases. The Company�s ophthalmology business includes repair, servicing and extended service contracts for its laser systems, and a capital component, consisting of the laser consoles combined with durable delivery devices (laser systems). Its laser consoles consist of IQ products, which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems and OcuLight products including OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems.

Officers and directors

William M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
James H. Mackaness Chief Financial Officer, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Ronald T. Steckel Vice President - Operations
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 47
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 73
Bio & Compensation  - Reuters
James B. Hawkins Independent Director
Age: 58
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters